Alzheimer’s Association International Conference
Jul 31 - Aug 4, 2022
Cognition’s vice president of research, Mary Hamby, Ph.D. presented proteomic analyses of disease biomarkers demonstrating the impact of CT1812 on disease processes in participants from the SPARC clinical study in mild-to-moderate Alzheimer’s disease.
CSF proteomics analysis to investigate the pharmacodynamic response of the S2R modulator CT1812 in Alzheimer’s disease patients from the SPARC clinical trial
Pandey K, Waybright L, Duong DM, Malagise E, Blennow K, Zetterberg H, Mecca AP, van Dyck C, Caggiano AO, Seyfried NT, Hamby ME
August 4, 2022 at 10:45 a.m. PT
San Diego Convention Center, San Diego, CA